well we all know that the triangle report cut the potential price more than half so if we just go with what they provided and ignore all other uses zantrene can and will be used for and ignore 3 to 5 time peak sales
At the very least we should receive $12billon minimum now I think this will be achieved if we wait till second lot of trials
So 12 bill divide by 200 mill gives you
$60 a share that is 100% more that I was expecting and now MR $30 will be
MR $60 a share
And that's still without adding 3 to 5 peak sales
Sure it's hard to believe because of the SP currently but I seen A2M go from $.60c to around $20
[ATTACH][ATTACH] well we all know that the triangle report cut...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.20 |
Change
-0.040(3.23%) |
Mkt cap ! $208.4M | |||
| Open | High | Low | Value | Volume |
| $1.24 | $1.24 | $1.20 | $103.7K | 85.92K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 12091 | $1.20 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.22 | 9720 | 1 |
View Market Depth
| Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
| RAC (ASX) Chart |